FOLFOX Delivery Method Could Offer Option in Unresectable Intrahepatic Cholangiocarcinoma
March 29th 2022The authors say delivering FOLFOX via transarterial infusion could be a “perfect option for treating intrahepatic cholangiocarcinoma before patients receive targeted therapy, immunotherapy, or radiotherapy.
Read More
Jonathan Kentley Discusses Applications of AI in Dermatology
March 28th 2022Jonathan Kentley, MBBS, MSc, research fellow at Memorial Sloan Kettering Cancer Center, explains ways artificial intelligence (AI) is being used in dermatology, including smartphone applications, at the 2022 American Academy of Dermatology Annual Meeting.
Watch
ASCO GU 2022: Comparing Tumor Genomic Landscape Across Age, Disease Demographics
March 28th 2022Posters from the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) 2022 look at how the tumor genomic landscape differs based on age and type of urothelial carcinoma.
Read More
Dr Bernice Kwong on GVHD: Empower Patients to Call on Doctors for Help
March 28th 2022Bernice Kwong, MD, clinical professor of dermatology, Stanford University, expands on her session about graft-versus-host disease diagnosis and management presented at the 2022 American Academy of Dermatology Annual Meeting, emphasizing the importance of the relationship between patients and doctors.
Watch
What We’re Reading: Epilepsy Drug Approval; Free COVID-19 Testing Ends; EPA Sued
March 28th 2022The FDA approved a drug to treat a rare form of childhood epilepsy; uninsured Americans will no longer have access to free COVID-19 tests; a conservation group is suing the Environmental Protection Agency (EPA) over failure to protect rivers from pollution.
Read More
Underscoring the Diversity Issue in Dermatology: Clinical Trials, Therapeutics, and Care Management
March 28th 2022Clinical trial recruitment and management strategies for diverse populations are among the challenges that affect dermatology care quality and access, according to panelists at the 2022 American Academy of Dermatology (AAD) Annual Meeting.
Read More
High CD47 Expression on HRS Cells Carries Poor Survival Implications in Classical HL
March 27th 2022Retrospective study findings show that CD47 expression on Hodgkin and Reed–Sternberg (HRS) cells varied between patients who had classical Hodgkin lymphoma (HL) and was associated with poor outcomes.
Read More
Dr David Rosmarin on Tailored Biologic Treatments, New Vitiligo Research
March 27th 2022David Rosmarin, MD, vice chair of research and education, Department of Dermatology, Tufts Medical Center, discusses best practices for choosing biologics, as well as his late-breaking findings on ruxolitinib cream for vitiligo at the 2022 American Academy of Dermatology (AAD) Annual Meeting.
Watch
Dr Robert Sidbury Summarizes Updated Atopic Dermatitis Guidelines at AAD 2022
March 27th 2022Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, sat down to discuss comorbidities newly associated with atopic dermatitis at the 2022 American Academy of Dermatology Annual Meeting.
Watch
Panel Reviews Dietary Triggers, Best Practices for Management of Dermatologic Diseases
March 27th 2022A panel discussion at the 2022 American Academy of Dermatology Annual Meeting addressed the association between food and skin manifestations, as well as dietary triggers and recommendations in the management of a myriad of dermatologic conditions.
Read More
Study Finds Low Natural Antibody Response to Clostridioides difficile
March 27th 2022The presence of antigen-specific and neutralizing antibodies was not associated with Clostridioides difficile infection symptoms, severity, therapy approach, treatment response, or recurrences in a new exploratory study.
Read More
People With HIV More Likely to Develop Hypertension After Starting INSTI-Based ART vs NNRTI
March 26th 2022Adults living with HIV receiving integrase strand transfer inhibitor (INSTI)–based antiretroviral therapy (ART) had a 76% higher incidence of hypertension compared with adults receiving non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Read More
Ruxolitinib Cream Shows Improved Efficacy, Sustained Safety in Vitiligo After Extended Follow-up
March 26th 2022Late-breaking findings at the 2022 American Academy of Dermatology Annual Meeting showed ruxolitinib cream was associated with clinically significant improvement in facial and total body repigmentation vs vehicle in the treatment of adolescent and adult patients with nonsegmental vitiligo over 52 weeks.
Read More